Skandigen intends to raise $4 million:
This article was originally published in Clinica
Executive Summary
Swedish biotechnology company Skandigen intends to raise SKr 27 million ($4 million) to fund development work of its various subsidiaries, most notably UK-based Fermentech (see Clinica No 666, p 14). Skandigen will issue 1.1 million new stock at a price of SKr 25 per share. The offer closed on August 18th.